In 2011, a team at Mayo Clinic did something no one had managed before: they built a tiny DNA construct, threaded it into the genome of a mouse, and used it to find and kill the “zombie cells” that accumulate in aging tissue. Those cells, known formally as senescent cells, had stopped dividing but refused to die, leaking inflammatory signals that poisoned their neighbors. When the researchers flipped the genetic switch and cleared them, the mice aged more slowly. That single experiment launched a research program that, by June 2026, has progressed from engineered mice to early human testing, producing the first peer-reviewed evidence that drugs inspired by that original DNA tool can reduce zombie-cell markers in living patients.
The DNA construct that started it all
The breakthrough hinged on a transgenic system called INK-ATTAC, a small DNA molecule designed to act as both a sensor and a weapon. Researchers Darren Baker and Jan van Deursen engineered it to detect cells producing p16Ink4a, a protein that accumulates when a cell enters senescence. Once the construct identified a p16-positive cell, it could trigger that cell’s self-destruction on command.
When Baker and van Deursen deployed INK-ATTAC in a progeroid mouse model, one engineered to age rapidly, clearing p16-positive cells delayed cataracts, muscle wasting, and fat loss. A follow-up study in naturally aging mice showed that p16-positive cells accumulating over a normal lifespan also shortened healthspan, the period of life free from serious disease. The implication was stark: zombie cells were not passive bystanders. They were active saboteurs.
“The INK-ATTAC experiments were proof of principle,” Baker told Mayo Clinic’s research magazine in a 2016 interview. “They showed us that if you can find and remove these cells, you can change the trajectory of aging.”
But a transgenic kill switch cannot be installed in a living person. The DNA construct was a discovery tool, not a therapy. The next challenge was finding drugs that could do what INK-ATTAC did in mice: selectively destroy senescent cells while leaving healthy tissue intact.
From genetic tool to drug candidates
Collaborators at Mayo Clinic and Scripps Research Institute mapped the internal survival networks that keep senescent cells alive. Unlike normal cells, zombie cells depend heavily on pro-survival pathways, essentially clinging to life through molecular safety nets that healthy cells do not need. By screening compounds that could cut those nets, the team identified a two-drug combination: dasatinib, an FDA-approved leukemia medication, and quercetin, a plant-derived flavonoid found in onions and apples.
The pairing worked because each compound exploited a different vulnerability. Dasatinib was more effective against senescent fat-cell progenitors, while quercetin targeted senescent endothelial cells lining blood vessels. That cell-type specificity is what made the approach selective rather than broadly toxic. The original screening study, published in Aging Cell in 2015, demonstrated that the combination killed senescent cells in culture and in living mice while sparing their normal counterparts.
Animal data reinforced the case. In a widely cited 2018 report, the National Institutes of Health described how senolytic drugs improved physical function in aging mice. Treated animals showed better treadmill endurance, stronger grip, and fewer signs of frailty compared with untreated peers. The results went beyond slowing decline. Clearing senescent cells appeared to allow tissues to partially recover from the chronic inflammatory stress those cells had been generating.
The first human evidence
The most significant step came in 2019, when Mayo Clinic investigators published results from a small pilot trial in patients with diabetic kidney disease. Nine participants received three intermittent doses of dasatinib plus quercetin over 11 days. Biopsies and blood draws showed that the treatment decreased senescent-cell markers in adipose tissue, skin, and circulating blood. Inflammatory molecules associated with the senescence-associated secretory phenotype, the toxic cocktail zombie cells release, also trended downward.
The trial, published in EBioMedicine (The Lancet Discovery Science), was deliberately small. It had no placebo control group and was designed primarily to test feasibility and short-term safety rather than long-term clinical outcomes. But it marked the first peer-reviewed human evidence that senolytics can reduce senescent-cell burden in living patients, not just in laboratory dishes or rodents.
As of mid-2026, several larger trials are underway or in planning stages, including studies targeting idiopathic pulmonary fibrosis, Alzheimer’s disease, and age-related frailty. Researchers at the Mayo Clinic Robert and Arlene Kogod Center on Aging have described these next-phase studies as critical for determining whether the biomarker changes seen in the pilot trial translate into functional improvements patients can actually feel.
What remains uncertain
The gap between a promising mouse result and a reliable human therapy remains wide, and researchers have been careful to say so.
No published data yet show whether clearing senescent cells in humans produces the kind of functional gains seen in mice: increased grip strength, faster walking speed, improved organ function. Those outcomes matter far more to patients than shifts in molecular markers, because they reflect real-world independence and quality of life.
Dosing is another open question. In mice, researchers control genetic background, diet, and timing with precision. Scaling senolytic regimens to diverse human populations, with varying ages, comorbidities, and medication lists, introduces variables the existing evidence does not address. Whether intermittent short courses of dasatinib and quercetin can be repeated safely over years, and whether the drugs reach senescent cells in every relevant tissue, has not been established in published trials.
There is also no direct evidence that senolytic treatment extends total human lifespan, as opposed to improving the quality of remaining years. The mouse data suggest healthspan gains, but lifespan extension in rodents does not automatically predict the same in people. Humans live far longer, face a wider range of environmental exposures, and develop complex, overlapping chronic illnesses that mice simply do not get.
Safety over the long term is unresolved. Dasatinib is a potent cancer drug with known side effects at oncologic doses, including low blood counts and bleeding risks. The senolytic trials have used much lower doses and intermittent schedules, and short-term tolerability has been acceptable. But rare adverse events may only surface when larger numbers of generally healthy older adults are treated and followed for years. Quercetin, while available over the counter as a dietary supplement, may behave differently at pharmacologic doses or when combined with prescription medications. Researchers have explicitly warned against self-experimentation with either compound.
It is also worth noting that not every senolytic approach has succeeded. Unity Biotechnology, a company that developed a different senolytic compound, saw its lead drug fail to outperform placebo in a 2020 clinical trial for osteoarthritis of the knee. That result underscored how difficult it is to translate the biology of senescence into therapies that work in specific human diseases.
A competing approach worth watching
Small-molecule drugs are not the only strategy under investigation. In 2024, researchers at Cold Spring Harbor Laboratory published a study showing that CAR-T cells, the engineered immune cells already used to treat certain blood cancers, could be programmed to seek and destroy senescent cells in mice. The approach offered a potential advantage: engineered immune cells might be more precise than chemical drugs, targeting only cells displaying specific surface markers of senescence. Early mouse data were promising, but the technology is years behind dasatinib-quercetin in terms of human testing, and CAR-T therapy carries its own serious risks, including cytokine release syndrome.
Meanwhile, the broader question of whether aging itself should be treated as a medical condition continues to gain traction. The TAME (Targeting Aging with Metformin) trial, organized by the American Federation for Aging Research, is designed to test whether the diabetes drug metformin can delay a composite of age-related diseases. If TAME succeeds, it could establish a regulatory framework for the FDA to evaluate drugs that target aging processes rather than individual diseases, a framework that would benefit senolytic research as well.
What this means for people following the science
The trajectory of senolytic research is genuinely notable. Few anti-aging strategies have moved from a clear biological mechanism (senescent cells cause tissue damage) to a targeted intervention (drugs that exploit those cells’ survival dependencies) to human testing within a single decade. That progression separates senolytics from many longevity claims that stall at the hypothesis stage or rely on untested supplements.
But the history of medicine is full of therapies that worked brilliantly in mice and failed in human trials, whether because of safety problems, lack of efficacy, or both. The next milestones to watch are larger, longer human trials that measure functional outcomes rather than just biomarkers. Researchers will need to show that clearing senescent cells can slow the progression of specific age-related diseases, such as kidney failure or heart failure, or delay the onset of frailty in at-risk older adults. Trials enrolling more diverse participants, including women and people from different racial and ethnic backgrounds, will also be essential to ensure any eventual therapies work broadly.
Until those results arrive, the best-supported conclusions are modest but meaningful. Zombie cells accumulate with age and actively contribute to tissue dysfunction. A tiny DNA construct proved they could be hunted and killed. Drugs inspired by that discovery can improve healthspan in mice, and an early human study has shown they can lower senescence markers in patients with diabetic kidney disease. What this does not yet mean is that senolytics are ready for routine clinical use or personal experimentation. They remain a promising research tool and a potential future therapy, not a proven anti-aging treatment.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
